Ascentage Pharma Group
AAPGAscentage Pharma Group (Stock Ticker: AAPG) is a clinical-stage biotechnology company based in China. Its primary business focus is the research and development of novel therapies targeting cancers, chronic hepatitis B, and age-related diseases. The company's drug discovery efforts are centered on modulating apoptosis and autophagy, which are fundamental biological pathways regulating programmed cell death and cellular degradation. The company's pipeline consists of multiple investigational assets, with a significant emphasis on oncology. Its lead candidates include apoptosis-targeting agents designed to inhibit key proteins such as IAP, MDM2-p53, and Bcl-2/Bcl-xL. Ascentage Pharma has advanced several of these candidates into clinical development stages across various hematologic malignancies and solid tumors globally. The company is publicly listed on the Hong Kong Stock Exchange. In addition to its oncology portfolio, Ascentage Pharma is developing therapeutics for chronic hepatitis B virus infection, aiming to achieve a functional cure by targeting viral replication and host immune pathways. The company operates with an integrated platform encompassing discovery, clinical development, and manufacturing capabilities to support its pipeline progression from preclinical research to late-stage clinical trials.
AAPG · Stock Price
Historical price data
About
Ascentage Pharma Group (Stock Ticker: AAPG) is a clinical-stage biotechnology company based in China. Its primary business focus is the research and development of novel therapies targeting cancers, chronic hepatitis B, and age-related diseases. The company's drug discovery efforts are centered on modulating apoptosis and autophagy, which are fundamental biological pathways regulating programmed cell death and cellular degradation. The company's pipeline consists of multiple investigational assets, with a significant emphasis on oncology. Its lead candidates include apoptosis-targeting agents designed to inhibit key proteins such as IAP, MDM2-p53, and Bcl-2/Bcl-xL. Ascentage Pharma has advanced several of these candidates into clinical development stages across various hematologic malignancies and solid tumors globally. The company is publicly listed on the Hong Kong Stock Exchange. In addition to its oncology portfolio, Ascentage Pharma is developing therapeutics for chronic hepatitis B virus infection, aiming to achieve a functional cure by targeting viral replication and host immune pathways. The company operates with an integrated platform encompassing discovery, clinical development, and manufacturing capabilities to support its pipeline progression from preclinical research to late-stage clinical trials.